SCHEDULE: Intracoastal Capital LLC Reports 4.99% Stake in Moleculin Biotech

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed a Schedule 13G, reporting beneficial ownership of 973,927 shares of Moleculin Biotech, Inc. common stock, representing 4.99% of the class.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the 'Reporting Persons') have filed a Schedule 13G.
• As of August 6, 2025, the Reporting Persons beneficially own 973,927 shares of Moleculin Biotech, Inc. common stock.
• This ownership represents approximately 4.99% of the outstanding common stock.
• The filing indicates that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the reporting persons holding a significant stake just below the 5% threshold, indicating a passive investment strategy rather than active engagement or positive outlook.

Positives

• The reporting persons hold a significant stake, indicating confidence in the company's potential.
• The filing is a standard disclosure for significant shareholders, providing transparency.

Negatives

• The ownership stake is precisely at 4.99%, just below the 5% threshold that would trigger more stringent reporting requirements, suggesting a passive investment approach.
• The filing does not provide any forward-looking statements or strategic insights into the company's performance or future plans.

Risks

• The blocker provisions in the warrants limit the ability to exercise them beyond certain ownership thresholds, capping potential upside for the reporting persons.
• The passive nature of the filing suggests a lack of active involvement in the company's strategic direction.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. The reporting persons' ownership is capped by blocker provisions in their warrants.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders. The 4.99% ownership level is strategic, allowing for substantial passive investment without triggering the more extensive disclosure requirements of a Schedule 13D.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant shareholder's stake, which may influence market perception.
• Management: The reporting persons' passive investment strategy suggests they are not seeking to influence corporate control or strategy at this time.

Next Steps

• The reporting persons will continue to monitor their investment in Moleculin Biotech, Inc.
• Any future changes in beneficial ownership exceeding reporting thresholds will necessitate further filings.

Key Dates

Keywords

Moleculin Biotech, Schedule 13G, Intracoastal Capital LLC, beneficial ownership, common stock, shareholder, SEC filing